Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The uncoating process of the herpes simplex virus (HSV) is a critical step in viral infection, involving the release of the viral genome from its protective capsid shell into the host cell nucleus. This process is essential for initiating viral gene expression and replication. It includes capsid transport to the nucleus, docking at nuclear pore complexes, and pressure-driven ejection of viral DNA into the nucleoplasm. Viral proteins like UL6 and UL25, along with host factors like importin β and Ran-GTP, play key roles. Targeting this process could block infection before gene expression begins, presenting a potential antiviral strategy.
Inhibition of viral genome release by blocking capsid docking to the nuclear pore complex or interfering with conformational changes required for DNA ejection.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Herpes Simplex Virus Uncoating Process (HSV Uncoating).